Brief: Actinium Announces Successful Pre-Planned Ad HOC Interim Analysis Of Phase 3 Sierra Trial
29/12/2020 13:37
Dec 29 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM ANNOUNCES SUCCESSFUL PRE-PLANNED AD HOC INTERIM
ANALYSIS OF PHASE 3 SIERRA TRIAL
* ACTINIUM PHARMACEUTICALS INC - INDEPENDENT DATA MONITORING
COMMITTEE RECOMMENDS SIERRA CONTINUE AS PLANNED TO FULL
ENROLLMENT OF 150 PATIENTS
* ACTINIUM PHARMACEUTICALS INC - TRIAL IS CURRENTLY OVER 75%
ENROLLED
* ACTINIUM PHARMACEUTICALS INC - DID NOT RECEIVE UNBLINDED
PRIMARY
AND SECONDARY ENDPOINT EFFICACY DATA FROM SIERRA.
Source text for Eikon: ID:nPn2S5n4Ba
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities